▶︎
Cell Therapies and Tissue-Based Products: Generating Scientific Evidence to Facilitate Development
▶︎
Fighting Antibiotic Resistance With Whole Genome Sequencing
▶︎
Understanding Endpoints in Rare Disease Drug Development
▶︎
193rd Vaccines and Related Biological Products Advisory Committee Meeting
▶︎
FDA Direct - Special Edition of FDA Direct
▶︎
AGDD 2025 | D2S03 - Common Deficiencies and Resolutions: Complex Drug Substance/Excipients/Products
▶︎
Conversations on Cancer: Religious Literacy and Spiritual Care for Patients and Caregivers
▶︎
Considerations for Collecting/Using Natural History Data Fit for Use in the Regulatory Setting
▶︎
AGDD 2025 | D1S02 - Novel Bioequivalence Study Design Recommendations
▶︎
AGDD 2025 | D2S04 - Nitrosamines: Known Issues and Practical Advice
▶︎
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers
▶︎
AGDD 2025 | D2S05 - Workshop Closing Remarks
▶︎
Office of New Drugs Custom Medical Queries(OCMQs) for Safety Signal Detection in Clinical Trial Data
▶︎
FDA Grand Rounds: FDA Menopausal Hormone Therapy (MHT) Labeling: Historical Context & Recent Changes
▶︎
AGDD 2025 | D2S04 – Session 4: Q&A Discussion Panel
▶︎
Financial Transparency & Efficiency of the Prescription Drug, Biosimilar, & Generic Drug User Fees
▶︎
AGDD 2025 | D1S02 - Session 2: Q&A Discussion Panel
▶︎
FDA Webinar: Safety Assessment of Genome Editing in Gene Therapy
▶︎
AGDD 2025 | D2S03-1 Session 3: Q&A Discussion Panel
▶︎